PTGS2 and endometriosis: More importantly, The Food and Drug Administration approved that selective COX-2 inhibitors with milder side effects (for example, rofecoxib and valdecoxib) can be used for the treatment of primary dysmenorrhea, and their long-term administration could potentially reduce the chronic pelvic pain associated with endometriosis [2].